Fig 2: Identification of human IFNGR1 and mouse Ifngr1 siRNA leads that efficiently modulate IFN-? signaling(A) Schematic of siRNA silencing IFN-? receptor for the modulation of IFN-? signaling. (B) Human IFNGR1 silencing in HeLa cells, (C) mouse Ifngr1 silencing in N2a cells, and (D) human IFNGR1 silencing in SH-SY5Y cells. Cells were treated with fully modified cholesterol-conjugated siRNAs at 1.5 µM for 72 h. The mRNA levels were measured by using QuantiGene 2.0 assays. siRNA number represents the 5' position of the mRNA target site. UNT, untreated control. Data are represented as percent of UNT (n = 3, mean ± standard deviation). (E) Dose-response curves of lead siRNA compounds (human 1726, mouse 1641). M, molar concentration of siRNA (n = 3, mean ± standard deviation). (F) Targeting region of lead siRNA in human IFNGR1 and mouse Ifngr1 mRNA.(G) Human CXCL9/10/11, and (H) Mouse Cxcl9/10/11 mRNA expressions (QuantiGene 2.0 assay) at 6 h post IFN-? signaling stimulation; cells were treated with siRNA at 1.5 µM for 72 h before IFN-? stimulation (n = 4, mean ± standard deviation, one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant).

Fig 3: Local distribution profile of DCA-siRNA in skin cell typesSingle injection of Cy3-labeled siRNA Ifngr1 1641 with or without DCA conjugation (at 3 different doses: 20, 10, 5 mg/kg in 150 µL PBS) were subcutaneously injected into mouse tail skin (a 25G, 40-mm needle was fully inserted and pulled slowly while injecting to cover approximately two-thirds of the area of the tail). Skin samples were collected at 48 h after the injection. (A) Images of skin biopsies from the injection site show local retention of siRNAs (pink), and (B) fluorescence microscopic images show siRNA (red) retention in local skin (nuclei were stained in blue with DAPI, original magnification ×20). (C) Hematoxylin and eosin staining (top) of skin biopsy distinguishes the morphology of epidermis and dermis (transverse section, arrows indicate stratum corneum, sebaceous gland, and hair follicle); Cy3-DCA-siRNA Ifngr1 1641 distribution (red in middle panel); PBS background staining (bottom panel); original magnification ×20, bar scale = 100 µm. (D) Percentage of Cy3-positive cell population in live epidermal cells (n = 3, mean ± standard deviation, 20 mg/kg DCA-siRNA Ifngr1 1641, and PBS background control, unpaired t-test, ****p < 0.0001), and (E) cell size-normalized median fluorescence intensity (MFI) indicates relative delivery efficiency of Cy3-siRNA in epidermal cell types (one-way ANOVA for multiple comparison; *p < 0.05, ****p < 0.0001; ns, not significant). (F) Percentage of Cy3 positive cell population in live dermal cells, and (G) normalized MFI in dermal cell types (***p < 0.001, ****p < 0.0001).

Fig 4: Chemical configurations of siRNA Ifngr1 1641 for gene silencing in mouse skin(A) Schematic of the chemical structures of hydrophobically conjugated (DCA; tri-myristic acid, Myr-t) and Dio siRNAs; DCA and Myr-t conjugates are covalently linked to the 3' end of sense strand; the two sense strands of the Dio scaffold are covalently linked by a tetraethylene glycol; the study also included unconjugated siRNA Ifngr1 1641 and DCA conjugated NTC siRNAs. (B) Ifngr1 mRNA silencing in skin at the injection site; mice (n = 5 per group) were injected subcutaneously (between shoulders) with a single dose of siRNA (20 mg/kg); local skin was collected at 1 week after injection and mRNA levels were measured using QuantiGene 2.0 assays; Ifngr1 expression was normalized to a housekeeping gene Ppib; data are represented as percent of PBS control (mean ± standard deviation) and analyzed by Kruskal-Wallis test (*p < 0.05, **p < 0.01; ns, not significant). (C) Efficacy of a single dose versus two doses (2×, 24 h apart; n = 5) of DCA-siRNA Ifngr1 1641 (One-way ANOVA, *p < 0.05, **p < 0.01). bDNA, branched DNA.

Fig 5: DCA-siRNA Ifngr1 1641 inhibits IFN-? signaling in an ex vivo skin model(A) Schematic of siRNA treatment in mice and stimulation of IFN-? signaling in an ex vivo skin biopsy model; mice (n = 5 per group) were treated subcutaneously with two doses (2×; 20 mg/kg; 2 weeks apart) of DCA-siRNA Ifngr1 1641 in tail skin, and eight punches per mouse of skin biopsies (4 mm in diameter) were collected. For each mouse, a seven-point dose response of IFN-? signaling stimulation was carried out using recombinant mouse IFN-? at a concentration range of 0–25.6 ng/mL. Skin biopsies were incubated at 37°C for 24 h, and CXCL9 and CXCL10 levels were determined by ELISA. (B–E) Production of CXCL9 and CXCL10 after the treatment of two scaffold configurations of DCA-siRNA Ifngr1 1641 (two-way ANOVA, ***p < 0.001, ****p < 0.0001).